Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Net Income towards Common Stockholders: 2013-2024

Historic Net Income towards Common Stockholders for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$413.6 million.

  • ImmunityBio's Net Income towards Common Stockholders rose 21.55% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 40.68%. This contributed to the annual value of -$413.6 million for FY2024, which is 29.15% up from last year.
  • As of FY2024, ImmunityBio's Net Income towards Common Stockholders stood at -$413.6 million, which was up 29.15% from -$583.9 million recorded in FY2023.
  • Over the past 5 years, ImmunityBio's Net Income towards Common Stockholders peaked at -$224.2 million during FY2020, and registered a low of -$583.9 million during FY2023.
  • In the last 3 years, ImmunityBio's Net Income towards Common Stockholders had a median value of -$417.3 million in 2022 and averaged -$471.6 million.
  • In the last 5 years, ImmunityBio's Net Income towards Common Stockholders slumped by 56.05% in 2021 and then grew by 29.15% in 2024.
  • ImmunityBio's Net Income towards Common Stockholders (Yearly) stood at -$224.2 million in 2020, then slumped by 56.05% to -$349.8 million in 2021, then decreased by 19.29% to -$417.3 million in 2022, then slumped by 39.91% to -$583.9 million in 2023, then increased by 29.15% to -$413.6 million in 2024.